3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
33
Lymphoma, Follicular
19
Lymphoma, Non-Hodgkin
16
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma
10
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma, B-Cell
5
Recurrence
4
Neoplasms
3
Leukemia, Hairy Cell
2
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Tumor Lysis Syndrome
1
Solid Tumors
1
Solid Cancers
1
Oncology Patients Receiving Chemotherapy
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Prolymphocytic
1
Leukemia, Lymphoid
1
Leukemia, B-Cell
1
Leukemia
1
Disease
1
Colorectal Neoplasms
1
Chromosome 17 deletion
1
Carcinoma, Non-Small-Cell Lung
1
Bronchiolitis Obliterans Syndrome
1
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Oncology Patients Receiving Chemotherapy
×
obinutuzumab
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts